Mednet Logo
HomeGynecologic Oncology
Gynecologic Oncology

Gynecologic Oncology

Clinical discussions on gynecologic malignancies, surgical approaches, and multimodal treatment strategies.

Recent Discussions

When would you hold anticoagulation medications in patients undergoing a tandem and ovoid/ring?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

We usually don’t hold unless planned for hybrid with needle placement. We would make sure sonogram is available for placement of tandem to avoid false track.

What is the best way to approach adjuvant therapy for a FIGO Stage IIIB clear cell carcinoma of uterus s/p TAH BSO, with pathology showing extensive involvement of LUS, the cervix, and bilateral parametria with positive parametrial margins?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

I wound get MRI imaging for pelvis to rule out gross disease and assuming staging is negative, would favor chemo RT to 50.4 Gy if not gross residual disease, followed by vaginal brachy boost and then additional chemo.

Are there known biomarkers predictive of IRAEs?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · St. Peter's Health Cancer Care

While there are no FDA-approved biomarkers predictive of iAEs, there is a growing body of preclinic and retrospective research trying to address this important question. Eosinophilia may be a potentially useful biomarker and this is supported by several retrospective studies 1,2. It is intriguing th...

Would you give checkpoint inhibitor therapy to a cancer patient with known dermatomyositis given the association of checkpoint inhibitor associated myocarditis, myasthenia gravis, and myositis?

1
6 Answers

Mednet Member
Mednet Member
Rheumatology · University of Washington

I think the dermatomyositis could be more paraneoplastic that would actually benefit from controlling the cancer with ICI. I would give the treatment but I would carefully follow-up the patient for any irAEs. I will also document the rheumatological assessment, CPK, and myositis panel before startin...

How do you discern whether elevated liver enzymes are from immunotherapy versus chemotherapy when a patient is on combination chemo/immunotherapy?

2
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Scripps MD Anderson Cancer Center

There is no consensus on the best method for distinguishing the cause of elevated liver enzymes in patients being treated with ICPi's when combined with various chemotherapies. Important considerations include time of onset, severity, and presence of hepatobiliary metastases. Hepatotoxicity from ICP...

Do you consider younger patients with NF2 to have a relative contraindication to radical pelvic RT due to risk of secondary malignancy?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Kentucky

Yes, I would consider NF2 to be a relative contraindication in a young patient. In the situation presented (borderline indications for post-op RT), I would likely lean toward up-front radical hysterectomy. However, if clear indications for post-op RT are present following surgery, I would not hesita...

How do you manage metastatic breast cancer to the uterus/ovaries that is symptomatic?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Management would be based on overall disease status, performance status, systemic treatment options, and expected survival. It tends to be seen more so in lobular carcinoma. Options could be from surgical debunking to quad shot based on the above.

When do you refer patients for germline testing when somatic tumor testing is negative for actionable mutations?

2
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Minnesota–Masonic Cancer Center

Somatic (tumor-only) testing should not be used to conclusively rule in or rule out the presence of a germline pathogenic/likely pathogenic alteration. While most germline sequence alterations (point mutations, small insertions/deletions) will be detected on tumor-only testing, this may miss chromos...

How do you approach RT coverage of an abdominopelvic lymph node in the oligometastatic or oligorecurrent setting?

3
5 Answers

Mednet Member
Mednet Member
Radiation Oncology · MD Anderson Cancer Center

Speaking specifically about prostate cancer, after treating a number of these with SBRT and having them fail in an adjacent node, me and everyone in our group will tend to treat the entire nodal chain with an SIB to the grossly involved LNs. The only exceptions are in those patients where prior RT p...

In uterine cancer, how does positive peritoneum biopsy influence your recommendation for adjuvant RT?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

It is stage IV disease and routine value of any adjuvant RT is very limited.